InsidersTradesSigma
Follow the MESOBLAST LIMITED stock price and the full directors' dealings record of the company, a listed issuer based in Australia. Shares are listed on the AU market, under the supervision of ASX. Market capitalisation: €3.1bn. The full history is free.
Analysts rate MESOBLAST LIMITED Strong Buy (bullish), based on 4 analysts. Average price target: A$3.93.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
No declarations found
0 of 0 declarations
MESOBLAST LIMITED is a biopharmaceutical company focused on developing cell therapies for serious diseases. It is listed on the Australian Securities Exchange (XASX).